Baidu
map

会议报道

订阅

MedSci主页 / 所有栏目 / 会议报道

比较氟维司群与阿那曲唑治疗晚期乳腺癌的多中心、随机、双盲、双模拟、安慰剂对照的Ⅲ期临床试验

2010-09-19 MedSci原创 MedSci原创

乳腺癌徐兵河研究
关注

　　报告者：中国医学科学院肿瘤医院徐兵河 　　时间：9 月17 日10:00～10:20 　　地点：16 区1 层大宴会厅 　　氟维司群是一种雌激素受体（ER）“灭活剂”，本研究比较了氟维司群和芳香化酶抑制剂阿那曲唑对曾接受抗激素治疗失败的中国女性晚期乳腺癌患者的疗效和安全性。  　　234例患者随机分入氟维司群250 mg/月（121例）或阿那曲唑1 m

　　报告者：中国医学科学院肿瘤医院徐兵河

　　时间：9 月17 日10:00～10:20

　　地点：16 区1 层大宴会厅

　　氟维司群是一种雌激素受体（ER）“灭活剂”，本研究比较了氟维司群和芳香化酶抑制剂阿那曲唑对曾接受抗激素治疗失败的中国女性晚期乳腺癌患者的疗效和安全性。 

　　234例患者随机分入氟维司群250 mg/月（121例）或阿那曲唑1 mg/日（113例）治疗组。主要研究终点为TTP，次要研究终点包括ORR、缓解期（DoR）、临床受益率（CBR）以及至治疗失败时间（TTF）。 

　　本研究结果表明，氟维司群250 mg和阿那曲唑对曾接受内分泌治疗进展或复发的中国绝经后晚期乳腺癌妇女具有相似的疗效和很好的耐受性。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-12-23 luoxiaog

    #多中心#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-06-27 amyloid

    #对照#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 wleon8895

    #安慰剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 jiangfeng5068

    #阿那曲唑#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 dinorsor527

    #Ⅲ期临床#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 xlxchina

    #双盲#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 guoyibin

    #安慰剂对照#

    0

相关资讯

2009版乳腺癌NCCN指南(中文版)

2009_乳腺癌_NCCN_指南中文版.pdf

Baidu
map
Baidu
map
Baidu
map